Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Boyce Burge who wrote (829)	1/26/1999 9:40:00 PM
From: lnkennedy	Read Replies (1) \| Respond to of 1728

I found a little news worth repeating, a ten day old buy rating with review. Hope this is somewhat helpful. --- Affymetrix is the premier chip technology company in the biotech sector. The company is on track to generate $100 million in sales in 1999, up form $54 million in 1998. Both its gene expression chips and polymorphism chips will contribute significantly. Although the company is still expected to lose $1.00 in 1999, we estimate that it will break even in 2000. Investors should also keep in mind that part of the 1999 loss is due to the company's legal battles with both Hyseq and Incyte Pharmaceuticals. Without the legal bills, AFFX would lose about $0.50 in 1999. AFFX continues to sign up customers for its DNA chips. Over a dozen major pharmaceutical companies are now buying AFFX chips . These include American Home Products, Eli Lilly, Hoffman La Roche, Glaxo Wellcome, Merck, Novartis, Parke-Davis, Human Genome Sciences, Pfizer, and, most recently, Hoechst Marion Roussel and Rhone-Poulenc Rorer. Affymetrix technology is also finding its way into the new technology of microfluidics, which may revolutionize the diagnostic industry over the next few years. --- good investing,lnk.